Published articles

Search collections:

Sort by:	Display results:	Output format:

Published articles	4 records found	Search took 0.02 seconds.

10 p, 582.3 KB

Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma / López Corral, Lucia (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ; Caballero Velazquez, Teresa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; López-Godino, Oriana (Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación. IMIB. Universidad de Murcia) ; Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Pérez-Vicente, Sabina (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Fernandez Aviles, Francesc (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Krsnik, Isabel (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ; Morillo, Daniel (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ; Heras, Inmaculada (Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación. IMIB. Universidad de Murcia) ; Morgades, Mireia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Rifon, Jose (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Sampol, Antonia (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Iniesta, Francisca (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ; Ocio, Enrique M. (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ; Martin, Jesús (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Rovira Tarrats, Montserrat (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cabero, Martín (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ; Castilla-Llorente, Cristina (Hematology Department. Gustave Roussy Cancer Center) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Torres-Juan, Marta (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Moraleda, José María (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ; Martinez, Carmen (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Vázquez, Alejandro (Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana) ; Gutiérrez-García, Gonzalo (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Caballero, Dolores (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ; San-Miguel, J (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Mateos, M. V (Complejo Asistencial Universitario de Salamanca. Instituto de Investigación Biomédica de Salamanca) ; Pérez-Simón, José Antonio (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Universitat Autònoma de Barcelona
Multiple myeloma (MM) remains as an incurable disease and, although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative approach, most patients ultimately relapse, and their treatment remains challenging. [...]
2019 - DOI (Digital Object Identifier)

10.1016/j.bbmt.2019.04.026
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1703-1712

Detailed record -

7 p, 1.0 MB

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation : Experience of the Spanish Group of Hematopoietic Stem Cell Transplant / Bento, Leyre (Instituto de Investigación Sanitaria Islas Baleares) ; Bastida, José María (Hospital Universitario de Salamanca) ; Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ; García-Torres, Estefania (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ; Rivera, Daniel (Hospital Universitario de Salamanca) ; Bosch-Vilaseca, Anna (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; De Miguel, Carlos (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Martínez-Muñoz, María Esther (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Fernandez Aviles, Francesc (Hospital Clínic i Provincial de Barcelona) ; Roldán Galvan, Elisa (Hospital Universitari Vall d'Hebron) ; Chinea, Anabelle (Hospital Universitario Ramón y Cajal (Madrid)) ; Yáñez, Lucrecia (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Zudaire, Teresa (Complejo Hospitalario de Navarra) ; Vaz, Carlos Pinho (Instituto Português de Oncologia) ; Espigado, Ildefonso (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; López, Javier (Hospital Universitario Ramón y Cajal (Madrid)) ; Valcárcel, David (Hospital Universitari Vall d'Hebron) ; Duarte, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Cabrera, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Herrera, Concepción (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ; González-Porras, José Ramón (Hospital Universitario de Salamanca) ; Gutiérrez, Antonio (Instituto de Investigación Sanitaria Islas Baleares) ; Solano, Carlos (Hospital Clínic Universitari (València)) ; Sampol, Antonia (Instituto de Investigación Sanitaria Islas Baleares) ; Universitat Autònoma de Barcelona
Persistent thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Romiplostim and eltrombopag are the currently available thrombopoietin receptor agonists (TPO-RAs), and some studies with very small numbers of cases have reported their potential efficacy in the allo-SCT setting. [...]
2019 - DOI (Digital Object Identifier)

10.1016/j.bbmt.2019.05.023
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1825-1831

Detailed record -

10 p, 680.7 KB

Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma / Ahmed, Sairah (University of Texas) ; Kanakry, Jennifer A. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ; Ahn, Kwang Woo (Medical College of Wisconsin) ; Litovich, Carlos Alejandro (Medical College of Wisconsin) ; Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ; Aljurf, Mahmoud Deeb (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ; Bacher, Vera Ulrike (Inselspital. Bern University Hospital) ; Bejanyan, Nelli (Immunotherapy. Moffitt Cancer Center) ; Cohen, Jonathon B. (Emory University School of Medicine) ; Farooq, Umar (University of Iowa Hospitals and Clinics) ; Fuchs, Ephraim Joseph (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ; Bolaños-Meade, Javier (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ; Ghosh, Nilanjan S. (Levine Cancer Institute. Atrium Health) ; Herrera, Alex F. (City of Hope National Medical Center) ; Hossain, Nasheed (Loyola University Chicago-Stritch School of Medicine) ; Inwards, David (Mayo Clinic) ; Kanate, Abraham Sebastian (West Virginia University) ; Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ; Munshi, Pashna (Georgetown University Hospital) ; Murthy, Hemant S. (University Florida College of Medicine) ; Mussetti, Alberto (Institut Català d'Oncologia-Hospitalet) ; Nieto, Yago (University of Texas) ; Perales, Miguel-Angel (Memorial Sloan Kettering Cancer Center) ; Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Savani, Bipin N. (Vanderbilt University Medical Center) ; Seo, Sachiko (Dokkyo Medical University) ; Wirk, Baldeep Mona (Seattle Cancer Care Alliance) ; Yared, Jean A. (University of Maryland) ; Sureda, Anna (Institut Català d'Oncologia-Hospitalet) ; Fenske, Timothy S. (Medical College of Wisconsin) ; Hamadani, Mehdi (Medical College of Wisconsin) ; Universitat Autònoma de Barcelona
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. [...]
2019 - DOI (Digital Object Identifier)

10.1016/j.bbmt.2019.05.025
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1859-1868

Detailed record -

9 p, 406.9 KB

Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation / Saad, Ayman (The Ohio State University) ; Lamb, Lawrence (University of Alabama at Birmingham) ; Wang, Tao (Medical College of Wisconsin) ; Hemmer, Michael T. (Medical College of Wisconsin) ; Spellman, Stephen (National Marrow Donor Program/Be the Match) ; Couriel, Daniel R (Utah Blood and Marrow Transplant Program) ; Alousi, Amin (Anderson Cancer Center) ; Pidala, Joseph (H. Lee Moffitt Cancer Center) ; Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ; Agrawal, Vaibhav (Indiana University School of Medicine) ; Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ; Beitinjaneh, Amer (University of Miami) ; Bhatt, Vijaya Raj (University of Nebraska Medical Center) ; Buchbinder, David Kyle (Children's Hospital of Orange County) ; Byrne, Michael (Vanderbilt University Medical Center) ; Cahn, Jean-Yves (CHU Grenoble Alpes) ; Cairo, Mitchell S. (New York Medical College) ; Castillo, Paul A. (UF Health Shands Children's Hospital) ; Chhabra, Saurabh (Medical College of Wisconsin) ; Diaz, Miguel Angel (Hospital Infantil Universitario Nino Jesus) ; Farhan, Shatha (Henry Ford Hospital Bone Marrow Transplant Program) ; Floisand, Yngvar (The National Hospital) ; Frangoul, Haydar A. (Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute) ; Gadalla, Shahinaz M. (National Cancer Institute) ; Gajewski, James (Consultant at Lu Daopei Hospital) ; Gale, Robert Peter (Imperial College London) ; Gandhi, Manish (Mayo Clinic) ; Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center) ; Hamilton, Betty (Cleveland Clinic Taussig Cancer Institute) ; Hematti, Peiman (University of Wisconsin Hospital and Clinics) ; Hildebrandt, Gerhard C. (University of Kentucky) ; Kamble, Rammurti T. (Baylor College of Medicine) ; Kanate, Abraham S. (West Virginia University) ; Khandelwal, Pooja (Cincinnati Children's Hospital Medical Center) ; Lazaryn, Aleksandr (H. Lee Moffitt Cancer Center) ; MacMillan, Margaret (University of Minnesota Blood and Marrow Transplant Program) ; Marks, David I. (University Hospitals Bristol NHS Trust) ; Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ; Mehta, Parinda A. (Cincinnati Children's Hospital Medical Center) ; Nishihori, Taiga (H. Lee Moffitt Cancer Center) ; Olsson, Richard (Uppsala University) ; Patel, Sagar (Cleveland Clinic Foundation) ; Qayed, Muna (Emory University School of Medicine) ; Rangarajan, Hemalatha G. (Nationwide Children's Hospital) ; Reshef, R. (Columbia University Medical Center) ; Ringden, O. (Karolinska Institutet (Estocolm, Suècia)) ; Savani, B.N. (Vanderbilt University Medical Center) ; Schouten, H.C. (Academische Ziekenhuis) ; Schultz, K.R. (The University of British Columbia) ; Seo, S. (Dokkyo Medical University) ; Shaffer, B.C. (Memorial Sloan Kettering Cancer Center) ; Solh, M. (Northside Hospital) ; Teshima, T. (Hokkaido University Hospital) ; Urbano-Ispizua, Alvaro (Hospital Clínic i Provincial de Barcelona) ; Verdonck, L.F. (Isala Clinic) ; Vij, R. (Washington University School of Medicine) ; Waller, E.K. (Emory University) ; William, B. (The Ohio State University) ; Wirk, B. (Seattle Cancer Care Alliance) ; Yared, J.A. (University of Maryland) ; Yu, L.C. (Children's Hospital/Louisiana State University Medical Center) ; Arora, M. (University of Minnesota Medical Center) ; Hashmi, S. (Mayo Clinic) ; Universitat Autònoma de Barcelona
Data on whether the T cell dose of allogeneic peripheral blood stem cell (PBSC) products influences transplantation outcomes are conflicting. Using the Center for International Blood and Marrow Transplant Research database, we identified 2736 adult patients who underwent first allogeneic PBSC transplantation for acute leukemia or myelodysplastic syndrome between 2008 and 2014 using an HLA-matched sibling donor (MSD) or an 8/8-matched unrelated donor (MUD). [...]
2019 - DOI (Digital Object Identifier)

10.1016/j.bbmt.2019.05.007
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1875-1883

Detailed record -

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.